Regeneron's antibody drug added to UK Recovery trial of Covid treatments | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
June 13, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JUNE 13, 2025
Regeneron's antibody drug added to UK Recovery trial of Covid treatments

Coronavirus chronicle

Reuters
14 September, 2020, 05:20 pm
Last modified: 14 September, 2020, 05:24 pm

Related News

  • Regeneron's Covid antibody drug shows protection for up to 8 months
  • AstraZeneca antibody cocktail succeeds in late-stage study to treat Covid-19
  • Eli Lilly's antibody combination receives FDA emergency use authorization for Covid-19
  • Regeneron announces more positive results for Covid-19 treatment
  • AstraZeneca’s Covid-19 antibody drug heads into advanced trials

Regeneron's antibody drug added to UK Recovery trial of Covid treatments

The UK RECOVERY trial, which has been testing a range of potential Covid-19 treatments since it began in April, will compare the effects of adding REGN-COV2 - a lab-manufactured monoclonal antibody - to standard care

Reuters
14 September, 2020, 05:20 pm
Last modified: 14 September, 2020, 05:24 pm
The ultrastructural morphology exhibited by the 2019 Novel Coronavirus, which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, US January 29, 2020/Reuters
The ultrastructural morphology exhibited by the 2019 Novel Coronavirus, which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, US January 29, 2020/Reuters

The world's largest randomised trial of potential medicines for Covid-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised with the disease.

The UK RECOVERY trial, which has been testing a range of potential Covid-19 treatments since it began in April, will compare the effects of adding REGN-COV2 - a lab-manufactured monoclonal antibody - to standard care.

"This is the first drug actually designed for this disease," said Martin Landray, a professor of medicine & epidemiology at Oxford University who is co-leading the trial.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"There are lots of good reasons for thinking this might be really quite a powerful treatment," he told Reuters in an interview.

The addition of Regeneron's drug to the RECOVERY trial comes amid growing hopes that monoclonal antibodies may emerge as effective ways to treat Covid-19.

Until now, the RECOVERY trial had mostly been studying whether existing drugs could be re-purposed to tackle the new disease, and it has already found answers on a number of them.

In June and September, trial results showed that widely used steroids such as dexamethasone and hydrocortisone were able to reduce death rates among severely-ill Covid-19 patients

Also in June, RECOVERY trial results showed that the anti-malarial drug hydroxychloroquine, once touted by US President Donald Trump as a potential "game changer" in the pandemic, was of no benefit in treating Covid-19 patients.

Regeneron's REGN-COV2 cocktail, which the company is already testing in late-stage clinical trials in people, combines one Regeneron-made antibody and a second antibody isolated from people who have recovered after being infected with Covid-19.

The combination is designed to bind to the spike protein used by the new coronavirus to gain access to human cells, limiting the virus's ability to escape.

Regeneron developed the biological drug before linking up with Roche to expand its manufacturing capacity in hopes of meeting global demand, should the medicine prove effective. Regeneron would handle US sales, with Roche selling the medicine around the world.

Landray said his team had secured enough supply of the drug so that up to "several thousand" patients could be given it in the trial and compared with several thousand controls.

"Given that the second phase (of Covid-19 infections in the UK) seems to be coming now, it is a really good time to be starting this," he said.

The United States already has a $450 million deal for the cocktail in place, under the terms of which Regeneron will sell it around 70,000 to 300,000 potential treatment doses or 420,000 to 1.3 million prevention doses of REGN-COV2. Data is due later this month, Regeneron has said.

Alongside Regeneron, Eli Lilly, working with biotech firm AbCellera, is seen as a leading contender in the antibody race. In August it started testing whether its antibody can prevent Covid-19 infections in nursing homes. A separate trial testing the compound on recently diagnosed Covid patients may yield initial data in September or shortly after.

GlaxoSmithKline and partner Vir Biotechnology also began testing an experimental antibody on newly diagnosed Covid-19 patients late last month.

AstraZeneca is for now testing its antibody-based cocktail on healthy volunteers for tolerability.

Regeneron / Covid-19 Antibody Test

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BNP Acting Chairperson Tarique Rahman and Chief Adviser  Muhammad Yunus meet at Dorchester Hotel in London, UK on 13 June 2025. Photo: CA Press Wing
    Tarique arrives at Dorchester Hotel for meeting with Yunus
  • Rescuers work at the scene of a damaged building in the aftermath of Israeli strikes, in Tehran, Iran, June 13, 2025. Majid Asgaripour/WANA (West Asia News Agency) via REUTERS
    Israel hits Iran nuclear facilities, missile factories; Tehran launches 100 drones in retaliation
  • Energy adviser Fouzul Kabir Khan with other government officials during a visit to Sylhet gas field on 13 June 2025. Photo: TBS
    I would disconnect gas supply to every home in Dhaka if I could: Energy adviser

MOST VIEWED

  • Wreckage of a Boeing 787 Dreamliner showing part of its registration "VT-ANB" in Ahmedabad, India, June 12, 2025. REUTERS/Amit Dave
    Air India Dreamliner crashes into Ahmedabad college hostel, kills over 290
  • File Photo of Chief Adviser Muhammad Yunus: UNB
    Prof Yunus to receive Harmony Award from King Charles today
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Bangladesh mulls settlements with tycoons over offshore wealth: BB governor tells FT
  • Railway seeks Tk2,000cr foreign loans to revive coach assembly, modernise workshops
    Railway seeks Tk2,000cr foreign loans to revive coach assembly, modernise workshops
  • UK Prime Minister Keir Starmer, Chief Adviser Muhammad Yunus
    Disclosure of unconfirmed Yunus-Starmer meeting shows ‘diplomatic imprudence’: Analysts
  • Brother sues Latifur's daughter, widow over alleged forgery to seize control of Transcom
    Brother sues Latifur's daughter, widow over alleged forgery to seize control of Transcom

Related News

  • Regeneron's Covid antibody drug shows protection for up to 8 months
  • AstraZeneca antibody cocktail succeeds in late-stage study to treat Covid-19
  • Eli Lilly's antibody combination receives FDA emergency use authorization for Covid-19
  • Regeneron announces more positive results for Covid-19 treatment
  • AstraZeneca’s Covid-19 antibody drug heads into advanced trials

Features

Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

1d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

2d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

4d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

5d | Bangladesh

More Videos from TBS

Global oil prices soar

Global oil prices soar

43m | TBS World
What did Iran say in response to the Israeli attack?

What did Iran say in response to the Israeli attack?

1h | TBS World
Israel strikes Iran nuclear facilities

Israel strikes Iran nuclear facilities

1h | TBS World
Extended Eid holidays may reduce remittance inflows, expatriates turn to unofficial channels

Extended Eid holidays may reduce remittance inflows, expatriates turn to unofficial channels

13m | TBS Insight
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net